Skip to content
10-Q/A

Quarterly Report

NeuroOne Medical Technologies Corporation NMTC

0001213900-26-068307

← back to feed
Filed
Jun 12, 2026 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Jun 10, 2026 8.7M sh
Shares Diluted Q2 2026 · Mar 31, 2026 8.48M sh
Shares Diluted Q2 2026 · Mar 31, 2026 8.55M sh
Shares Diluted restated Q2 2026 · Mar 31, 2025 5.19M sh
Shares Diluted restated Q2 2026 · Mar 31, 2025 5.16M sh
Capex Q2 2026 · Mar 31, 2026 $79.27K
Capex Q2 2026 · Mar 31, 2025 $27.59K
Operating Cash Flow Q2 2026 · Mar 31, 2026 −$4.44M
Operating Cash Flow Q2 2026 · Mar 31, 2025 $151.91K
Cash And Equivalents Q2 2026 · Mar 31, 2026 $2.8M
Cash And Equivalents Q2 2026 · Sep 30, 2025 $6.57M
Stockholders Equity restated Q2 2026 · Mar 31, 2026 $5.08M
Stockholders Equity Q2 2026 · Dec 31, 2025 $6.4M
Stockholders Equity Q2 2026 · Sep 30, 2025 $7.07M
Stockholders Equity Q2 2026 · Mar 31, 2025 $1.13M
Stockholders Equity Q2 2026 · Dec 31, 2024 $2.94M
Stockholders Equity Q2 2026 · Sep 30, 2024 $822.01K
Current Liabilities Q2 2026 · Mar 31, 2026 $1.69M
Current Liabilities Q2 2026 · Sep 30, 2025 $2.3M
Total Liabilities Q2 2026 · Mar 31, 2026 $2.49M
Total Liabilities Q2 2026 · Sep 30, 2025 $3.71M
Current Assets restated Q2 2026 · Mar 31, 2026 $7.11M
Current Assets Q2 2026 · Sep 30, 2025 $10.23M
Total Assets restated Q2 2026 · Mar 31, 2026 $7.57M
Total Assets Q2 2026 · Sep 30, 2025 $10.79M
Eps Diluted restated Q2 2026 · Mar 31, 2026 −$0.28
Eps Diluted restated Q2 2026 · Mar 31, 2026 −$0.47
Eps Diluted restated Q2 2026 · Mar 31, 2025 −$0.44
Eps Diluted restated Q2 2026 · Mar 31, 2025 −$0.09
Eps Basic restated Q2 2026 · Mar 31, 2026 −$0.28
Eps Basic restated Q2 2026 · Mar 31, 2026 −$0.45
Eps Basic restated Q2 2026 · Mar 31, 2025 −$0.44
Eps Basic restated Q2 2026 · Mar 31, 2025 −$0.09
Sga Expense Q2 2026 · Mar 31, 2026 $1.92M
Sga Expense Q2 2026 · Mar 31, 2026 $3.8M
Sga Expense Q2 2026 · Mar 31, 2025 $1.94M
Sga Expense Q2 2026 · Mar 31, 2025 $3.98M
Rd Expense Q2 2026 · Mar 31, 2026 $1.47M
Rd Expense Q2 2026 · Mar 31, 2026 $2.86M
Rd Expense Q2 2026 · Mar 31, 2025 $1.51M
Rd Expense Q2 2026 · Mar 31, 2025 $2.68M
Net Income restated Q2 2026 · Mar 31, 2026 −$2.38M
Net Income restated Q2 2026 · Mar 31, 2026 −$3.82M
Net Income Q2 2026 · Dec 31, 2025 −$1.44M
Net Income Q2 2026 · Mar 31, 2025 −$2.27M
Net Income Q2 2026 · Mar 31, 2025 −$485.29K
Net Income Q2 2026 · Dec 31, 2024 $1.79M
Operating Income restated Q2 2026 · Mar 31, 2026 −$2.4M
Operating Income restated Q2 2026 · Mar 31, 2026 −$4.1M
Operating Income Q2 2026 · Mar 31, 2025 −$2.68M
Operating Income Q2 2026 · Mar 31, 2025 −$968.81K
Gross Profit restated Q2 2026 · Mar 31, 2026 $990.26K
Gross Profit restated Q2 2026 · Mar 31, 2026 $2.56M
Gross Profit Q2 2026 · Mar 31, 2025 $771.06K
Gross Profit Q2 2026 · Mar 31, 2025 $2.7M
Cost Of Revenue restated Q2 2026 · Mar 31, 2026 $871.79K
Cost Of Revenue restated Q2 2026 · Mar 31, 2026 $2.2M
Cost Of Revenue Q2 2026 · Mar 31, 2025 $615.49K
Cost Of Revenue Q2 2026 · Mar 31, 2025 $1.96M
Revenue restated Q2 2026 · Mar 31, 2026 $1.86M
Revenue restated Q2 2026 · Mar 31, 2026 $4.75M
Revenue Q2 2026 · Mar 31, 2025 $1.39M
Revenue Q2 2026 · Mar 31, 2025 $4.66M